HERZLIYA, Israel and CALGARY, Alberta , Oct. 9, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that Dr. Joseph V.
Pergolizzi, Jr. , M.D.
, a member of Innocan's Scientific Advisory Board, has been recognized among the top 2% most-cited scientists in the world in a new list published by Stanford University . This achievement underscores Dr. Pergolizzi's long-term contribution to medical science and his influential role in shaping global healthcare practices.
Dr. Pergolizzi was appointed to Innocan Pharma's Scientific Advisory Board in September 2023 . His role focuses on promoting pharmaceutical human product R&D and supporting the Company's planned FDA filing for new medications.
His expertise in pain management, critical care medicine, and regulatory processes are key in advancing Innocan's pharmaceutical developments. "We are incredibly proud of Dr. Pergolizzi's well-deserved recognition as one of the most-cited scientists worldwide," said Iris Bincovich, CEO of Innocan Pharma .
"His recognition as part of Stanford University's top 2% is a reflection of his dedication to advancing medical research. His expertise has been pivotal in advancing our R&D efforts and aligning them with FDA regulatory pathways. I congratulate Dr.
Pergolizzi on this outstanding honor and look forward to continuing our strong collaboration as we wor.